Publications by authors named "Mary Beth Karow"
Article Synopsis
- The Mayo-Baylor RIGHT 10K Study focused on using pharmacogenomics to improve drug prescriptions based on genetic information in a large population.
- Researchers sequenced the DNA of over 10,000 participants to identify genetic variations affecting drug responses, and integrated these findings into electronic health records.
- Results showed that 79% of participants had actionable genetic variants affecting their medication, highlighting the need for a proactive approach to personalized medicine in clinical care.
Clinical pharmacogenomic testing typically uses targeted genotyping, which only detects variants included in the test design and may vary among laboratories. To evaluate the potential patient impact of genotyping compared with sequencing, which can detect common and rare variants, an in silico targeted genotyping panel was developed based on the variants most commonly included in clinical tests and applied to a cohort of 10,030 participants who underwent sequencing for CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, DPYD, SLCO1B1, TPMT, UGT1A1, and VKORC1. The results of in silico targeted genotyping were compared with the clinically reported sequencing results.
View Article and Find Full Text PDF